In phase 2 trial, novel therapy significantly reduced triglyceride levels
· Medical Xpressedited by Gaby Clark, reviewed by Andrew Zinin
Gaby Clark
Scientific Editor
Meet our editorial team
Behind our editorial process
Andrew Zinin
Chief Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add to Preferred Sources
A phase 2b clinical trial led by Mass General Brigham Heart and Vascular Institute researchers shows that a monoclonal antibody therapy called MAR001 can significantly reduce triglyceride levels within 12 weeks for patients with high triglyceride levels. Their results are published in the New England Journal of Medicine and were presented simultaneously at the American Heart Association's annual meeting.
"Despite advances in lipid-lowering therapy, many patients continue to have elevated triglyceride levels and cardiovascular risk," says lead author Michelle O'Donoghue, a cardiologist with the Mass General Brigham Heart and Vascular Institute and senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group. "Our findings suggest that MAR001 may be able to safely and effectively lower triglycerides."
Several classes of drugs have been previously shown to lower triglycerides, but MAR001 is novel because it targets ANGPTL4, a protein that naturally inhibits lipoprotein lipase, an enzyme that breaks down triglycerides.
The researchers tested the effectiveness of three different doses of MAR001 in 235 participants with elevated triglyceride levels. Participants were randomly assigned to receive either a placebo or 300, 450 or 900 mg of MAR001 subcutaneously every four weeks for 24 weeks. The trial was designed by the Mass General Brigham Thrombolysis in Myocardial Infarction (TIMI) Study Group with the sponsor Marea Therapeutics, and participants received treatment at 48 centers across the United States, Canada, Australia and New Zealand.
MAR001 was effective at lowering fasting triglyceride levels and demonstrated a statistically significant, placebo-adjusted reduction in fasting triglyceride levels of 39.1% to 45.5% across three MAR001 dose levels at week 12. MAR001 treatment was not associated with more frequent adverse effects compared to the placebo.
More research is needed to understand the long-term effects and to assess whether these reductions in triglycerides reduce the risk of pancreatitis and other complications of high triglycerides. In the next phase of the study, the researchers will test MAR001 in participants with severely elevated levels of triglycerides.
"We observed greater reductions in triglycerides in participants with higher baseline triglyceride levels," says O'Donoghue. "We're now evaluating this in a dedicated follow-up study."
Publication details
ANGPTL4 Inhibition in Adults with Elevated Triglycerides, New England Journal of Medicine (2026). DOI: 10.1056/NEJMoa2612463
Journal information: New England Journal of Medicine
Key medical concepts
Clinical categories
CardiologyClinical pharmacologyCommon illnesses & Prevention Provided by Mass General Brigham Who's behind this story?
Gaby Clark
MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →
Andrew Zinin
Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →
Citation: In phase 2 trial, novel therapy significantly reduced triglyceride levels (2026, November 9) retrieved 9 November 2026 from https://medicalxpress.com/news/2026-11-phase-trial-therapy-significantly-triglyceride.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.